Sugi Predict

Sugi Predict / Compounds / SCHEMBL2435580

SCHEMBL2435580

SCHEMBL2435580

Cn1ccc2c(F)cccc21

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RHEB Q15382 1/20 0.66
▸ HTR2A P28223 1/20 0.50
▸ HTR2C P28335 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.48
▸ NQO2 P16083 1/20 0.47
▸ HSD11B1 P28845 4/20 0.42
▸ ASH1L Q9NR48 1/20 0.41
▸ TRPV3 Q8NET8 1/20 0.39
▸ FABP4 P15090 1/20 0.39
▸ TUBB4A P04350 1/20 0.38
▸ TUBB P07437 1/20 0.38
▸ TUBA3C P0DPH7 1/20 0.38
▸ TUBA1B P68363 1/20 0.38
▸ TUBA4A P68366 1/20 0.38
▸ TUBB4B P68371 1/20 0.38
▸ TUBB3 Q13509 1/20 0.38
▸ TUBB2A Q13885 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30373755 1.00 RHEB (0.66) RHEBHTR2AHTR2CKDM4EALDH1A1
SCHEMBL23709824 0.80 RHEB (1.00) RHEBKDM4EALDH1A1MAPTRXFP1
SCHEMBL256208 0.76 ALDH1A1 (0.50) RHEBHTR2AHTR2CKDM4EALDH1A1
SCHEMBL18230319 0.75 RHEB (0.45) RHEBHTR2AHTR2CKDM4EALDH1A1
SCHEMBL17867534 0.75 HTR2C (0.59) RHEBHTR2AHTR2CP2RX7
SCHEMBL1092615 0.74 HSD11B1 (0.57) RHEBKDM4EALDH1A1MAPTRXFP1
SCHEMBL21893432 0.74 ALDH1A1 (0.48) RHEBHTR2AKDM4EALDH1A1MAPT
SCHEMBL21863280 0.74 MAPT (0.48) RHEBKDM4EALDH1A1MAPTRXFP1
SCHEMBL1138076 0.74 KDM4E (0.48) RHEBKDM4EALDH1A1MAPTRXFP1
SCHEMBL24721604 0.74 HTR2A (0.46) RHEBHTR2AHTR2CMAPTFABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116969967-A Synthesis method of polysubstituted-5, 10-dihydro [1,2,3,4] tetrathio [5,6-b:7,8-b' ] diindole and derivative 衡阳师范学院 2023-10-31 — — CN claimed
CN-116813639-A Synthesis method of polysubstituted [1,2,3,4,5] pentathio [6,7-b ] indole and derivative 衡阳师范学院 2023-09-29 — — CN claimed
CN-106995400-B A kind of compound and its salt and its synthetic method 湘潭大学 2019-08-06 — — CN claimed
CN-106995400-A A kind of compound and its salt and its synthetic method 湘潭大学 2017-08-01 — — CN claimed
CN-106117113-A Polysubstituted carbazole, derivant and synthetic method thereof 湘潭大学 2016-11-16 — — CN claimed
US-20250263760-A1 MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2025-08-21 — — US disclosed
US-12319946-B2 Methods for producing modified bacteria for production of nitroaromatics UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2025-06-03 — — US disclosed
CN-115974845-B Preparation method of Ornitinib intermediate 奥锐特药业股份有限公司 2024-09-20 — — CN disclosed
US-20240229090-A1 MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-07-11 — — US disclosed
WO-2024130344-A1 TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS UNIQUEST PTY LIMITED (AU) 2024-06-27 — — WO disclosed
EP-3896063-B1 CRYSTALLINE FORMS OF THE SYK INHIBITOR 5-FLUORO-1-METHYL-3-[[5-[4-(3-OXETANYL)-1-PIPERAZINYL]-2-PYRIDINYL]AMINO]-6-(1H-PYRAZOL-3-YL)-2(1H)-QUINOLINONE HYDROCHLORIDE SALT (1:1) CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2024-01-24 — — EP disclosed
US-11879144-B2 Modified bacteria for production of nitroaromatics UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-01-23 — — US disclosed
US-20080027067-A1 Heterocyclic derivatives as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2008-01-31 — — US disclosed
US-20080027067-A1 Heterocyclic derivatives as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2008-01-31 — — US disclosed
WO-2007075895-A2 HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-07-05 — — WO disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 — — US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 — — US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 — — US disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 — — US disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027067-A1 Heterocyclic derivatives as modulators of ion channels TRPV1, KCNJ2, KCNN3 RHEB 1985/4885HTR2A 457/4885HTR2C 491/4885
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 RHEB 2848/4885HTR2A 2878/4885HTR2C 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.